Literature DB >> 30341187

TRAF2 Deficiency in B Cells Impairs CD40-Induced Isotype Switching That Can Be Rescued by Restoring NF-κB1 Activation.

Rachel A Woolaver1, Xiaoguang Wang1, Yonatan Dollin1, Ping Xie2,3, Jing H Wang4, Zhangguo Chen4.   

Abstract

Effective humoral immunity requires class switch recombination (CSR) catalyzed by activation-induced cytidine deaminase (AID). In response to T cell-dependent (TD) Ags, CSR can be induced by CD40 signaling in B cells. TNFR-associated factors 2 and 3 (TRAF2/TRAF3) function as adaptors of the CD40 signaling pathway. B cell-intrinsic TRAF2 or TRAF3 (B-TRAF2 or B-TRAF3) knockout mice were previously reported to have indistinguishable phenotypes in gene expression, B cell survival and development, and enlarged peripheral lymphoid organs. However, it remains unknown whether deficiency of B-TRAF2 or B-TRAF3 differentially affects TD humoral immune responses and CD40-induced CSR. In this article, we show that B-TRAF2 is essential for optimal isotype switching induced by in vivo TD Ag immunization or by engaging CD40 in vitro. Our data clarify the controversial role of B-TRAF3 and confirm its dispensability in CD40-induced CSR. Mechanistically, CD40-induced AID expression was markedly impaired by B-TRAF2, but not B-TRAF3, deficiency. Moreover, B-TRAF2 deficiency causes defective activation of the NF-κB1 complex in a CD40-autonomous manner, and restoring CD40-induced NF-κB1 activation in TRAF2-deficient B cells rescues AID expression and CSR. We conclude that TRAF2 is essential but TRAF3 is dispensable for TD humoral immunity and CD40-induced CSR. Our studies provide significant biological bases for optimizing treatment of B cell-associated immune disorders by targeting CD40 signaling.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30341187      PMCID: PMC6246814          DOI: 10.4049/jimmunol.1800337

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

1.  The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching.

Authors:  Haifa Jabara; Dhafer Laouini; Erdyni Tsitsikov; Emiko Mizoguchi; Atul Bhan; Emanuela Castigli; Fatma Dedeoglu; Vadim Pivniouk; Scott Brodeur; Raif Geha
Journal:  Immunity       Date:  2002-09       Impact factor: 31.745

Review 2.  AID targeting in antibody diversity.

Authors:  Rushad Pavri; Michel C Nussenzweig
Journal:  Adv Immunol       Date:  2011       Impact factor: 3.543

3.  CD40 ligand-transduced co-stimulation of T cells in the development of helper function.

Authors:  D van Essen; H Kikutani; D Gray
Journal:  Nature       Date:  1995-12-07       Impact factor: 49.962

4.  TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor.

Authors:  Sandra Gardam; Frederic Sierro; Antony Basten; Fabienne Mackay; Robert Brink
Journal:  Immunity       Date:  2008-02-28       Impact factor: 31.745

5.  Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).

Authors:  P Revy; T Muto; Y Levy; F Geissmann; A Plebani; O Sanal; N Catalan; M Forveille; R Dufourcq-Labelouse; A Gennery; I Tezcan; F Ersoy; H Kayserili; A G Ugazio; N Brousse; M Muramatsu; L D Notarangelo; K Kinoshita; T Honjo; A Fischer; A Durandy
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

Review 6.  Molecular mechanisms of antibody somatic hypermutation.

Authors:  Javier M Di Noia; Michael S Neuberger
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

Review 7.  TRAF3 as a powerful and multitalented regulator of lymphocyte functions.

Authors:  Gail A Bishop
Journal:  J Leukoc Biol       Date:  2016-05-06       Impact factor: 4.962

8.  BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathway.

Authors:  Egest J Pone; Jinsong Zhang; Thach Mai; Clayton A White; Guideng Li; John K Sakakura; Pina J Patel; Ahmed Al-Qahtani; Hong Zan; Zhenming Xu; Paolo Casali
Journal:  Nat Commun       Date:  2012-04-03       Impact factor: 14.919

9.  HoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutation.

Authors:  Seok-Rae Park; Hong Zan; Zsuzsanna Pal; Jinsong Zhang; Ahmed Al-Qahtani; Egest J Pone; Zhenming Xu; Thach Mai; Paolo Casali
Journal:  Nat Immunol       Date:  2009-04-12       Impact factor: 25.606

10.  Roles of the kinase TAK1 in CD40-mediated effects on vascular oxidative stress and neointima formation after vascular injury.

Authors:  Zifang Song; Xiaolei Zhu; Rong Jin; Cuiping Wang; Jinchuan Yan; Qichang Zheng; Anil Nanda; D Neil Granger; Guohong Li
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

View more
  5 in total

1.  TRAF3 Acts as a Checkpoint of B Cell Receptor Signaling to Control Antibody Class Switch Recombination and Anergy.

Authors:  Zhangguo Chen; Alexandra Krinsky; Rachel A Woolaver; Xiaoguang Wang; Samantha M Y Chen; Vince Popolizio; Ping Xie; Jing H Wang
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

2.  Ginkgolide C attenuates lipopolysaccharide‑induced acute lung injury by inhibiting inflammation via regulating the CD40/NF‑κB signaling pathway.

Authors:  Rui Zhang; Nan Guo; Genquan Yan; Qian Wang; Tiantian Gao; Baoke Zhang; Ning Hou
Journal:  Int J Mol Med       Date:  2021-03-02       Impact factor: 4.101

Review 3.  How the Signaling Crosstalk of B Cell Receptor (BCR) and Co-Receptors Regulates Antibody Class Switch Recombination: A New Perspective of Checkpoints of BCR Signaling.

Authors:  Zhangguo Chen; Jing H Wang
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

Review 4.  Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study.

Authors:  Hui Yu; Liangbin Lin; Zhiqiang Zhang; Huiyuan Zhang; Hongbo Hu
Journal:  Signal Transduct Target Ther       Date:  2020-09-21

Review 5.  The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease.

Authors:  Laura A Bosmans; Lena Bosch; Pascal J H Kusters; Esther Lutgens; Tom T P Seijkens
Journal:  J Cardiovasc Transl Res       Date:  2020-03-28       Impact factor: 4.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.